The mechanism-independent nature of the PRS platform makes it utilizable to treat a broad spectrum of diseases including for the treatment of cancers, infectious diseases, and for organ transplants. Oncology Optimization of combination therapies is of particular importance in oncology. Conventional cancer treatments often rely on the sequential use of chemotherapy drugs, with each new drug starting as soon as the pervious agent loses efficacy. However, this methodology allows allows for cancerous cells, due to their rapid rate of mutation, to develop resistances to chemotherapy drugs in instances where chemotherapy drugs fail to be effective. Combination therapies are therefore vital to preventing the development of drug resistant tumors and thereby decreasing the likelihood of relapse among cancer patients. The PRS platform alleviates the principal difficulty in developing combination therapies to treat cancer as it omits the need to perform in-vitro high throughput screening to determine the most effective regimen that is currently employed. PRS based therapy has been used to successful derive a optimized 3 drug combination to treat multiple myeloma and overcome drug resistance. The PRS derivative CURATE.AI platform has also been used to optimize a 2 drug combination of a bromodomain inhibitor and enzalutamide to successfully treat and prevent the progression of prostate cancer. Infectious disease Drug resistance is a particular challenge when attempting to treat infectious diseases as monotherapy solutions carry the risk of increasing drug resistance and combination therapy demonstrates lower mortality rates. Highly contagious infectious diseases like tuberculosis have become the leading cause of death by infectious disease world wide. Tuberculosis treatment requires the sustained use of antibiotics over an extended period of time, with high rates of noncompliance among patients, which increases the risk of development of drug resistant forms of tuberculosis. The PRS platform has been successfully used to develop combinatory regimens that reduce tuberculosis treatment time by 75% and can be employed on both drug sensitive and resistant variants of the disease. The PRS derivative IDENTIF.AI platform has been used in Singapore to identify viable SARS-CoV-2 delta variant treatments on behalf of the Singapore Ministry of Health. The platform identified the metabolite EIDD-1931 as having strong antiviral properties that can be used in combination with other commercial antiviral agents to create an effective therapy for the treatment of the SARS-CoV-2 delta variant. Organ transplant The PRS derived<unk>  personalized dosing platform developed in 2016 has been used to provide personalized tacrolimus and prednisone dosing for liver transplant procedures and post transplant care to prevent transplant rejection events. This methodology is able to use the minimal number of calibration tests and as a result provides a physicians with a rolling window in which daily optimized drug dose can be predicted. The platform is recalibrated daily to take into consideration the patients changing physiological<unk> s to the drug regimen providing physicians with accessible personalized treatment tools and eliminating the need to use of population average based dosing. The platform is actively being considered for other transplant uses including kidney and heart transplants.
Phenotypic response surfaces
Lewis antigen system
Kell antigen system
Lutheran antigen system
Killing Season
MNS antigen system
Helper/suppressor ratio
Kidd antigen system